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Abstract
Painful distal sensory polyneuropathy (DSP) is the most common neurological complication of HIV1
infection. Although infection with the virus itself is associated with an incidence of DSP, patients
are more likely to become symptomatic following initiation of nucleoside reverse transcriptase
inhibitor (NRTI) treatment. The chemokines monocyte chemoattractant protein-1 (MCP1/CCL2)
and stromal derived factor-1 (SDF1/CXCL12) and their respective receptors, CCR2 and CXCR4,
have been implicated in HIV1 related neuropathic pain mechanisms including NRTI treatment in
rodents. Utilizing a rodent model that incorporates the viral coat protein, gp120, and the NRTI,
2'3'-dideoxycytidine (ddC), we examined the degree to which chemokine receptor signaling via
CCR2 and CXCR4 potentially influences the resultant chronic hypernociceptive behavior. We
observed that following unilateral gp120 sciatic nerve administration, rats developed profound
tactile hypernociception in the hindpaw ipsilateral to gp120 treatment. Behavioral changes were
also present in the hindpaw contralateral to the injury, albeit delayed and less robust. Using
immunohistochemical studies, we demonstrated that MCP1 and CCR2 were upregulated by
primary sensory neurons in lumbar ganglia by post-operative day (POD) 14. The functional nature
of these observations was confirmed using calcium imaging in acutely dissociated lumbar dorsal
root ganglion (DRG) derived from gp120 injured rats at POD 14. Tactile hypernociception in gp120
treated animals was reversed following treatment with a CCR2 receptor antagonist at POD 14.
Some groups of animals were subjected to gp120 sciatic nerve injury in combination with an
injection of ddC at POD 14. This injury paradigm produced pronounced bilateral tactile
hypernociception from POD 14–48. More importantly, functional MCP1/CCR2 and SDF1/CXCR4
signaling was present in sensory neurons. In contrast to gp120 treatment alone, the
hypernociceptive behavior associated with the injury plus drug combination was only effectively
reversed using the CXCR4 antagonist AMD3100. These studies indicate that the functional
upregulation of CCR2 and CXCR4 signaling systems following a combination of gp120 and an NRTI
are likely to be of central importance to associated DSP and may serve as potential therapeutic
targets for treatment of this syndrome.
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Peripheral neuropathy is the most common neurological
complication associated with HIV1 infection. The most
common form of neuropathy is a sensory polyneuropathy
or HIV1 sensory neuropathy (HIV-SN). HIV-SN can be
subdivided into distal sensory polyneuropathy (DSP) and
antiretroviral induced toxic neuropathy (ATN). Both
forms involve sensory loss and neuropathic pain. DSP
occurs in up to 35% of HIV1 infected individuals, while
ATN develops following highly active antiretroviral ther-
apy (HAART) treatment in up to 52% of patients [1].
The mechanisms underlying HIV-SN remain unclear.
While evidence of neuronal infection by HIV1 is lacking,
it is well known that components of the virus such as the
coat protein gp120 can bind to, and signal via, neuronal
CXCR4 or CCR5 chemokine receptors [2]. Chemokines
are well known to direct leukocyte trafficking during
inflammatory responses, but numerous studies have now
shown additional roles for chemokines that include neu-
ral development and modulation of nervous system
responses to injury and disease [3,4]. Furthermore, it is
known that peripheral sensory neurons can be strongly
excited by chemokines and by gp120 [5-7]. As neuronal
excitation is a central feature in chronic pain conditions,
it is not surprising that a number of chemokine receptors
and their ligands have been implicated in multiple rodent
models of chronic hypernociception [8].
Previous reports involving gp120 and the nervous system
have suggested that gp120 contributes to neurotoxicity
and nociceptive behavior in rodents [9-16]. The events
that lead to these effects in the nervous system may be
dependent on human CD4 (hCD4) binding and confor-
mational changes in gp120 enabling it to bind to chemok-
ine receptors with high affinity [17]. Alternatively, some
of the toxic effects of gp120 may be independent of hCD4
binding and be mediated by alternative mechanisms
[18,19].
Proposed mechanisms underlying gp120 induced chronic
nociception include spinal gliosis. However, peripheral
studies in the rodent have shown that perineural gp120
exposure without the addition of hCD4 is accompanied
by nerve pathology (distal degeneration of unmyelinated
sensory fibers, decreased fiber density and axonal swell-
ing) and an upregulation of proinflammatory cytokine
expression [9,10,15]. Despite several investigations into
gp120 associated mechanisms underlying chronic
mechanical hypernociception, few studies have examined
the role of chemokine receptors in gp120 induced
mechanical hypernociception in the presence of hCD4.
Painful peripheral neuropathy associated with the use of
nucleoside reverse transcriptase inhibitors (NRTIs), a
component of HAART, is clinically quite common
[20,21], although the mechanisms underlying this phe-
nomenon are yet to be determined. We previously dem-
onstrated that the NRTI, 2'-3'-dideoxycytidine (ddC) not
only produced mechanical hypernociceptive behavior but
also upregulated CXCR4 mediated chemokine signaling
in glia and neurons present in sensory ganglia. Moreover,
an antagonist of the CXCR4 receptor, AMD3100, reversed
drug induced mechanical hypernociception [22].
Changes in chemokines are not limited to SDF1 as sys-
temic treatment with ddC, nerve treatment with gp120, or
a combination of the two treatments also produces pro-
nounced changes in MCP1/CCL2 in sensory neurons of
the DRG [15]. Despite emerging evidence that chemokine
signaling is central to NRTI induced mechanical hyperno-
ciception, little is known regarding the mechanisms
underlying the effects of NRTIs in combination with
gp120/hCD4, which would represent a closer approxima-
tion to the clinical situation.
In order to answer such questions, in the present series of
experiments we have tested the hypothesis that perineural
gp120/hCD4 treatment alone produces changes in neuro-
nal chemokine signaling and animal behavior. The com-
bination of both gp120/hCD4 and the NRTI further
modifies the effects of perineural gp120/hCD4 on animal
behavior and chemokine signaling. We have also pharma-
cologically validated the associated changes in chemokine
signaling and associated alterations in mechanical sensi-
tivity with chemokine receptor antagonists.
Methods
Animals
Pathogen-free, adult female Sprague-Dawley rats (150–
200 g; Harlan Laboratories, Madison, WI) were housed in
temperature (23 ± 3°C) and light (12-h light: 12-h dark
cycle; lights on at 07:00 h) controlled rooms with stand-
ard rodent chow and water available ad libitum. Experi-
ments were performed during the light cycle. All animals
were subjected to behavioral assays prior to treatment and
randomly assigned to one of experimental or sham treat-
ment groups. These experiments were approved by the
Institutional Animal Care and Use Committee of Loyola
University, Chicago. All procedures were conducted in
accordance with the Guide for Care and Use of Laboratory
Animals published by the National Institutes of Health
and the ethical guidelines of the International Association
for the Study of Pain. Most animal studies include at least
6–8 animals for treatment groups. The data derived from
the initial trial for each experiment was analyzed with
Power = 95% to determine if sample sizes must be modi-
fied for any particular experiment to achieve statistical sig-
nificance (P < 0.05).Page 2 of 18
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Animals were anesthetized with 4% isoflurane and main-
tained on 2% isoflurane (Halocarbon, River Edge, NJ) in
O2. For the gp120 paradigm, we performed the injury as
done previously, with a few modifications [15]. For all
gp120 experiments, rgp120 HIV-1 IIIB (Euk, Immunodi-
agnostics) was dissolved in buffered sterile saline (pH 7.4)
to give a final concentration of 800 ng. This solution was
combined with 4 μl recombinant human CD4 (hCD4), a
glycoprotein coreceptor for gp120 [23], reconstituted in
0.1% BSA/PBS solution (100 μg/ml). The right sciatic
nerve of the rat was exposed at the mid-thigh level under
sterile conditions. A sterile polyvinyl acetal (PVAc) sponge
(Ivalon, San Diego, CA), 2-mm × 2-mm saturated with the
gp120 solution, was placed adjacent to the sciatic nerve.
The dermal incision site was closed with 5.0 suture thread.
Sham control animals were prepared as described above,
but buffered sterile saline was used in place of gp120/
hCD4 plus saline.
For the gp120/hCD4 in combination with the NRTI
model, animals underwent the same procedure described
above. At post-operative day (POD) 14, the animals were
given a single intraperitoneal (i.p.) injection of the NRTI,
2',3'-dideoxycytidine (ddC, 25 mg/kg; Sigma) freshly pre-
pared in saline. This dose was found to be effective in a
previous study (Bhangoo et al., 2007b). Vehicle injections
were single i.p. injections of saline.
Drugs and method of administration
A CCR2 receptor antagonist and its inactive enantiomer,
both gifts of Eli Lilly and Co, were employed in this study
[24]. The CCR2 antagonist active enantiomer's full name
is (R)-4-Acetyl-1-(4-chloro-2-fluorophenyl)-5-cyclohexyl-
3-hydroxy-1,5-dihydro-2H-pyrrol-2-one (CCR2 RA [R]),
and it was used as a Na+ salt. Some animals were given a
saline vehicle injection. Both compounds were freshly
prepared in saline on the day of the experiment (10 mg/
kg). Receptor antagonist and vehicle-treated groups (n = 8
per group) were given a single i.p. injection one hour prior
to behavioral testing. The bicyclam, AMD3100 (5 mg/kg,
Sigma), was also used. These treated animals were also
given a single i.p. injection of this CXCR4 receptor antag-
onist one hour prior to behavioral testing. Antagonist dos-
ages were determined in previous studies [22,24].
Foot withdrawal to punctate mechanical indentation
The incidence of foot withdrawal was measured in
response to mechanical indentation of the plantar surface
of each hindpaw with Von Frey-type filaments. Mechani-
cal stimuli were applied with seven filaments, each differ-
ing in the bending force delivered (10, 20, 40, 60, 80, 100,
and 120 mN). Each filament was fitted with a flat tip and
a fixed diameter of 0.2 mm [22,25-27]. The force equiva-
lence of mN to grams is: 100 mN equals 10.197 g.
The rat was placed on a metal mesh floor and covered
with a transparent plastic dome. Typically, the animals
rest quietly in this situation after an initial few minutes of
exploration. Animals were habituated to this testing appa-
ratus for 15 minutes a day, two days prior to the behavio-
ral assays. Following acclimation, each filament was
applied to six locations spaced across the hind paw that
correspond to the nerve distribution in the glabrous skin.
The filaments were tested in order of ascending force, with
each filament delivered in sequence from the 1st to the
6thlocation alternating from one hindpaw to the other.
The duration of each stimulus was 1 second and the inter-
stimulus interval was 10–15 seconds. A cutoff value of
120 mN was used; animals that did not respond at 120
mN were assigned that value [22,27]. In each behavioral
testing sequence, the operator was blinded to the animal
treatment condition.
The incidence of paw withdrawal was expressed as a per-
centage of the six applications of each filament as a func-
tion of force. A Hill equation was fitted to the function
(Origin version 6.0, Microcal Software, Northhampton
MA) relating the percentage of indentations eliciting a
withdrawal to the force of indentation. From this equa-
tion, the paw withdrawal threshold (PWT) force was
obtained and defined as the force corresponding to a 50%
withdrawal. At least a -20 mN difference from the baseline
PWT in a given animal is representative of mechanical
hypernociception [22,27].
Measurements were taken on three successive days before
surgery. Postoperative testing was performed on post-
operative day (POD) 5, 7, 10, 14 and weekly thereafter for
the duration of the experiment. PWT values were statisti-
cally analyzed for each foot separately and for the signifi-
cance of differences between the average of the three
preoperative tests and the mean obtained for each postop-
erative test. The same statistical analyses are applied to the
slopes of the logistic functions from which the PWTs were
derived. The experimenter was blinded to both the injury
condition of the animal and the drugs utilized in all
behavioral trials.
Foot withdrawal to thermal stimulus
To evaluate the PWT to thermal stimulation, the Har-
greaves' plantar test apparatus (Ugo Basile, Varese, Italy)
was used. Rats were placed on a 2-mm-thick glass floor; a
mobile infrared heat generator with an aperture of 10 mm
was aimed at the rat's hindpaw under the floor. Following
activation of the heat source, the reaction time (the with-
drawal latency of the hindpaw) of the rat was recorded
automatically. A shortening of the withdrawal latency
indicated thermal hyperalgesia. The temperature of the
glass floor was kept at 22.5–23.5°C. Measurements of the
withdrawal latency of the paw began after the rats werePage 3 of 18
(page number not for citation purposes)
Molecular Pain 2009, 5:48 http://www.molecularpain.com/content/5/1/48habituated to the testing environment (IR setting = 70).
The measurements were repeated three times, at 5 min
intervals, on each paw. The averages of the three pairs of
measurements taken were employed as data.
In situ hybridization
In situ hybridization histochemistry for chemokine recep-
tors was performed by using digoxigenin-labeled ribo-
probes. Adult female Sprague-Dawley rats were
euthanized using carbon dioxide. L4L5 DRGs ipsi- and
contralateral to LPC nerve injury were rapidly removed,
embedded in OCT compound (Tissue Tek, Ted Pella, Inc.,
Redding, CA) and frozen. Sections were serially cut at 14
μm. The CCR2 probe was prepared as previously
described [7]. Briefly, an 848-bp CCR2 cDNA fragment
(nucleotides 489–1336 of GenBank no. U77349) was
cloned by PCR using rat spleen cDNA. The resulting PCR
product was subcloned into a pGEM-T Easy vector and
sequenced to ensure identity for riboprobe use. The CCR2
template was linearized with SacII to generate a probe of
950 bases by using SP6 polymerase. Signals were visual-
ized by using NBT/BCIP reagents (Roche Diagnostics/
Boehringer Mannheim, Indianapolis, IN) in the dark for
2–20 h depending upon the abundance of the RNA. The
CXCR4 and SDF1 probes were generated as described pre-
viously [3]. Images were captured using brightfield or dif-
ferential interference contrast optics with a Nikon E600
fluorescent microscope (NikonUSA, Melville, NY) fitted
with a charge-coupled device camera (Retiga EXi, Q-Imag-
ing Corporation, Vancouver, BC).
Immunohistochemical labeling
Adult female Sprague-Dawley rats were euthanized with
CO2 and transcardially perfused with saline followed by
4% paraformaldehyde. Lumbar ganglia associated with
the sciatic nerve ipsilateral to the nerve injury (n = 6) or
sham treatment (n = 6) were immediately removed and
post fixed for 4 hours. Additional lumbar DRGs were
removed from naïve, behaviorally tested rats (n = 6). Lum-
bar DRGs were encoded at the outset and processed in
random order. Sagittal sections of the DRG were serially
cut at 14 μm onto SuperFrost Plus microscope slides
(Fisher Scientific, Pittsburgh PA). At least 6 sections were
obtained for immunohistochemical analysis per DRG.
Tissue was processed such that DRG sections on each slide
were at intervals of 80 um. Slides were incubated with
blocking buffer (3% serum/0.4% Triton-X; Fisher Scien-
tific, Pittsburgh PA) for 1 hour, followed by overnight
incubation with anti-MCP1 (rabbit polyclonal, 1:500;
Chemicon, Temecula, CA), CXCR4 (rat monoclonal,
1:20,000; BD Pharmingen) or CCR2 (rabbit polyclonal,
1:500; Aviva Systems Biology, San Diego CA) at room
temperature. After primary incubation, slides were incu-
bated in secondary antibodies (goat conjugated to CY2,
Jackson ImmunoResearch, West Grove, PA) which were
used to visualize cells. For some double-labeling experi-
ments, slides were then incubated in anti-TRPV1 antibody
(rabbit polyclonal, 1:1000; Neuromics), followed by
incubation in secondary antibodies (donkey conjugated
to CY5). Some experiments were augmented with the
addition of IB4 conjugated with fluorescein (1 mg/1 ml;
Sigma, St. Louis MO). Slides were washed in PBS for 5 min
each (x3) and coverslipped with a PBS/glycerol solution.
All tissue sections were also stained with DAPI nuclear
marker (Invitrogen Corporation, Carlsbad CA).
Tissue sections were analyzed for the presence of TRPV1 or
IB4-binding neurons and either CXCR4 or CCR2. Because
a stereological approach was not employed in this study,
quantification of the data may represent a biased estimate
of the actual numbers of immunopositive neurons. The
proportions of immunoreactive neurons were determined
from the total number of DAPI-positive neuronal nuclei
present in a tissue section. The overall diameter and
brightness of the DAPI-positive neuronal nuclei allowed
for a clear delineation between neurons and non-neuro-
nal cells in the DRG. A positive cell was considered to be
one with clear cytoplasmic staining, and the outline of the
nucleus was apparent. At least 2000 neuronal profiles
from six animals were quantified for each cell type in the
single neuronal marker study and for each combination of
cellular markers. Quantification of cell numbers and
degree of colocalization was determined using Image J
(National Institute of Health). Data are represented as
means ± SEM%.
Preparation of acutely dissociated dorsal root ganglion 
cells
The L4-L5 DRG were acutely dissociated using methods
described by Ma and LaMotte [28]. Briefly, L4 and L5 DRG
were removed from sham control or treated animals at
various post-operative time points. The DRGs were treated
with collagenase A and collagenase D in HBSS for 20 min-
utes (1 mg/ml; Roche Applied Science, Indianapolis, IN),
followed by treatment with papain (30 units/ml, Wor-
thington Biochemical, Lakewood, NJ) in HBSS containing
.5 mM EDTA and cysteine at 35°C. The cells were then dis-
sociated via mechanical trituration in culture media con-
taining 1 mg/ml bovine serum albumin and trypsin
inhibitor (1 mg/ml, Sigma, St. Louis MO). The culture
media was equal amounts of Ham's F12 mixture and
DMEM supplemented with 10% fetal bovine serum and
penicillin and streptomycin (100 ug/ml and 100 U/ml).
The cells were then plated on cover slips coated with poly-
L-lysine and laminin (1 mg/ml) and incubated for 2 hours
before more culture media was added to the wells. The
cells were then allowed to sit undisturbed for 12–15 hours
to adhere at 37°C (with 5% CO2).Page 4 of 18
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The dissociated DRG cells were loaded with fura-2 AM (3
uM, Molecular Probes/Invitrogen Corporation, Carlsbad
CA) for 25 minutes at room temperature in a balanced salt
solution (BSS) [NaCl (140 mM), Hepes (10 mM), CaCl2
(2 mM), MgCl2 (1 mM), Glucose (10 mM), KCl (50
mM)]. The cells were rinsed with the BSS and mounted
onto a chamber that was placed onto the inverted micro-
scope and continuously perfused with BSS at a rate of 1
ml/min. Intracellular calcium was measured by digital
video microfluorometry with an intensified CCD camera
coupled to a microscope and MetaFluor software (Molec-
ular Devices Corporation, Downington, PA). Cells were
illuminated with a 150 W xenon arc lamp, and the excita-
tion wavelengths of the fura-2 (340/380 nm) were
selected by a filter changer. Chemokines were applied
directly into the cover slip bathing solution after the per-
fusion was stopped. If no response was seen within 1
minute, the chemokine was washed out. For all experi-
ments, interferon-γ-induced protein 10 (IP-10/CXCL10),
MCP1 and SDF1 were added to the cells in random order,
after which capsaicin, high K+ (50 K) and ATP were
added. The chemokines used were purchased from R & D
Systems (Minneapolis, MN), and all were used at a con-
centration of 100 nm to ensure maximal activation. They
were reconstituted in 0.1%BSA/PBS, and aliquots were
stored at -20°C. A minimum of 50 neurons was analyzed
for each chemokine.
Statistical Analyses
Data is presented as the mean ± SEM, unless otherwise
noted. GB-Stat School Pack software (Dynamic Microsys-
tems, Inc. Silver Springs, MD) and Graphpad Prism
(GraphPad Software, Inc.) were used to statistically evalu-
ate all data. Significant differences were determined by
one-way ANOVA with Bonferroni's post-hoc test for ani-
mal behavior. A one-way ANOVA with a Dunnett's Multi-
ple Comparison test was used to analyze the differences
between naïve, sham and experimental groups in the fura
imaging studies. A difference of p < 0.05 was considered
significant.
Results
Perineural gp120/hCD4 treatment produces mechanical 
hypernociception in the hindpaw ipsilateral to the injury
After establishing a baseline behavioral assessment, rats
were treated with a perineural application of either vehicle
(saline), or gp120/hCD4 in saline (n = 6–8/group). Rats
treated with gp120/hCD4 displayed mechanical hyperno-
ciception (-20 mN change in PWT) as measured by graded
von Frey filaments in the limb ipsilateral to the injury by
POD 5 (Fig. 1A; n = 10, p < 0.001) and in the limb con-
tralateral to the injury by POD 17 (Fig. 1A; n = 10, p <
0.01). The force required to elicit a PWT remained signifi-
cantly below baseline thresholds until POD 28 for the
hindpaw contralateral to the lesion and POD 35 for the
hindpaw ipsilateral to the injury. Vehicle treated sham
operated rodents did not exhibit a PWT decrease that was
significant at any time point (Fig. 1A). Upon completion
of testing, rats were euthanized and tissues utilized for fur-
ther analysis.
Perineural gp120/hCD4 treatment in combination with 
ddC produces bilateral mechanical hypernociception
A single i.p. injection of ddC was administered at day 14
after an initial perineural treatment with gp120/hCD4
treatment (n = 8). As opposed to the largely unilateral
changes in PWT observed at 17 days following gp120/
hCD4 treatment, the addition of the ddC treatment fur-
ther diminished PWT in both hindpaws. This change in
PWT occurred within 3 days of the ddC injection (Fig. 1B;
n = 10, p < 0.01). Similar to previous observations [22],
the lowest PWTs were exhibited by 7 days post ddC injec-
tion. These bilateral injury induced changes lasted for at
least 49 days (data not shown).
Perineural gp120/hCD4 and ddC produce differential 
effects on thermal thresholds
The thermal PWTs of the gp120/hCD4 treated rats from
POD 0–14 (10.38 +/- .17 seconds) did not differ from the
baseline threshold (10.57 +/- .55 seconds; Fig. 1C; n = 10,
or from vehicle treated rodents (data not shown). In con-
trast, the thermal withdrawal thresholds of rats treated
with a combination of gp120/hCD4 and ddC at POD 14
were reduced to 7.18 +/- .73 seconds when compared with
baseline thresholds (10.38 +/- .17 seconds). This differ-
ence in the latency withdrawal (-3.2 ± 0.09 s) was signifi-
cantly different (Fig. 1C; n = 10, p < 0.05).
Injury induced alteration of CCR2 mRNA and protein 
expression in lumbar DRG
Lumbar DRGs removed from naive failed to exhibit CCR2
immunopositive cells (see additional file 1A) or CCR2
mRNA cells (see additional file 1C). Likewise, vehicle-
treated rats at POD 14 failed to exhibit CCR2 mRNA (Fig.
2A) or CCR2 immunopositive cells (Fig. 2B). Following
perineural gp120/hCD4, sensory neurons in the lumbar
DRG ipsilateral to the focal nerve injury were observed to
express CCR2 mRNA transcripts (Fig. 2C) and were
immunopositive for CCR2 (Fig. 2D). The neuronal
expression of CCR2 mRNA in rodents subjected to both
gp120/hCD4 and the NRTI did not differ from gp120/
hCD4 treatment alone (Fig. 2E–F). Moreover, the number
of CCR2 immunopositive neurons present in gp120/
hCD4 treated DRG (27.8 ± 1.9% of total neurons) or in
combination with ddC (24.15 ± 1.5% of total neurons)
did not exhibit significant differences.
In an attempt to further establish the identity of CCR2
immunopositive sensory neurons, we performed doublePage 5 of 18
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Mechanical and thermal behavioral responses following perineural gp120/hCD4 treatment alone or in combination with a single 25 mg/kg i.p injection of 2'-3'-dideoxycytidineFigure 1
Mechanical and thermal behavioral responses following perineural gp120/hCD4 treatment alone or in combi-
nation with a single 25 mg/kg i.p injection of 2'-3'-dideoxycytidine. A) Rats were assessed for low-threshold mechan-
ical sensitivity (von Frey test) at 3, 7, 10, 14, 17, 28 days following perineural gp120/hCD4 treatment. Reduced behavioral 
thresholds for the hindpaw ipsilateral to the nerve lesion (black square) were significantly different from pre-operative baseline 
from post-operative day (POD) 3–28. The threshold force for the hindpaw contralateral to the nerve lesion (black diamond), 
did not meet the pre-determined criteria indicative of mechanical hypernociceptive behavior until POD17. The time course of 
sham injury did not differ from the uninjured animals (ipsilateral sham, black circle; contralateral sham, black triangle). (n = 10; 
* p < 0.01). POD: post-operative day after gp120/hCD4 treatment. B) Mean threshold force required for paw withdrawal to 
Von Frey stimulation following perineural gp120/hCD4 treatment and a single 25 mg/kg i.p injection of 2'-3'-dideoxycytidine 
(ddC; n = 10). The ddC injection was given on POD14 after gp120 treatment. Reduced behavioral thresholds for the hindpaw 
ipsilateral (black square) and contralateral (black diamond) to the nerve treatment were seen as early as POD17/post-injection 
day (PID) 3 and reached the lowest levels by POD21/PID7 (p < 0.01). The time course of sham injury did not differ from the 
uninjured animals (ipsilateral sham, black circle; contralateral sham, black triangle). C) gp120/hCD4 induced nerve injury did 
not produce changes in thermal responses as assessed by the Hargreaves test. Each bar is the mean withdrawal latency (± SE) 
of the hindpaw ipsilateral (white bar) or contralateral (black bar) to the nerve injury at POD 7 and 14 (n = 10). After a single 
i.p. injection of ddC at POD 14, thermal hyperalgesia was observed as early as PID 3 and reached the shortest latency by PID7 
in the paws ipsilateral and contralateral to the gp120/hCD4 treatment. POD: post-operative day after gp120/hCD4 treatment; 


































































































































































Molecular Pain 2009, 5:48 http://www.molecularpain.com/content/5/1/48labeling immunofluorescence with well established neu-
rochemical markers of key sensory neuron subpopula-
tions. Neuronal binding of the plant isolectin, IB4 in the
rat DRG distinguishes a non peptidergic subpopulation of
C-fiber nociceptors that project largely to spinal cord dor-
sal horn lamina II [29,30]. Many IB4 binding neurons
were present in lumbar DRG of sham operated rats and
those subjected to gp120/hCD4 and the combination of
gp120/hCD4 and ddC (Fig. 3A, B, C, and 3G). 32 ± 2% of
the total neurons were positive for IB4 in DRG derived
from sham treated rodents. Following gp120/hCD4 treat-
ment, 27.8 ± 1.9% of neurons were immunopositive for
CCR2 and approximately half of those cells were colocal-
ized with IB4 (53.6 ± 0.8%; Fig. 3G). Sensory neurons in
DRG derived from gp120/hCD4 and ddC treated rodents
(n = 6) displayed similar numbers of neurons that bound
IB4 and were CCR2 immunopositive (51.3 ± 1%).
Coexpression of the TRPV1 receptor channel with CCR2 
receptors
We performed double labeling immunofluorescence for
the vanilloid receptor TRPV1, a ligand gated cation chan-
nel that is responsive to several diverse stimuli and impor-
tant in nociceptive pain responses. We found that in sham
treated tissues, 30.8 ± 1.3% of neurons expressed the
TRPV1 protein, while there was no CCR2 expression (Fig.
3D, G). Fourteen days after perineural gp120/hCD4 treat-
ment, the number of neurons expressing TRPV1 had not
changed (27 ± 1.7%). However, as mentioned above,
numerous CCR2 immunopositive cells were present and
nearly half of these cells colocalized with TRPV1 (48 ±
1.6% Fig. 3E, G). The combination of gp120/hCD4 and
ddC treatment did not produce significant changes in the
percentage of colocalized CCR2/TRPV1 immunopositive
neurons when compared with rodents subjected to
perineural gp120/hCD4 (46.2 ± 0.78%; Fig. 3F, G).
Injury induced alteration of CXCR4 mRNA and protein 
expression in lumbar DRG
In addition to CCR2, other chemokine receptors may also
be involved in neuropathic pain mechanisms. To estab-
lish the degree to which CXCR4 signaling is evident in
rodents subjected to perineural gp120/hCD4 alone or in
combination with ddC, we first determined to what extent
this chemokine receptor was altered by the same injury
paradigms as discussed above. One example of this is
SDF1 signaling via CXCR4 receptors. Peripheral nerves
constitutively express the chemokine SDF1 and its recep-
tor CXCR4, and basal expression of SDF1 and CXCR4
mRNA in the rat is predominantly detected in non-neuro-
nal cells of the lumbar DRG derived from naïve animals
[22]. Subsequent to peripheral nerve injury or ddC treat-
ment both SDF1 and CXCR4 exhibit increased expression
[31-33].
Consistent with previous observations, immunohisto-
chemical techniques used in these experiments revealed
non-neuronal CXCR4 immunoreactivity present in both
naïve (see additional file 1B and 1D) and sham treated
sensory neurons (Fig. 4A, B). This level of non-neuronal
Expression of CCR2 mRNA and protein immunoreactivity in rat lumbar DRG ipsilateral to gp120/hCD4 nerve treatment and ddC treatment at post- perative day (POD) 14 and 21Figure 2
Expression of CCR2 mRNA and protein immunore-
activity in rat lumbar DRG ipsilateral to gp120/hCD4 
nerve treatment and ddC treatment at post-opera-
tive day (POD) 14 and 21. A) Lumbar DRG removed 
from vehicle-treated animals at POD14 did not exhibit CCR2 
mRNA expression (n = 3). B) There was no evidence of 
CCR2 protein expression in sham animals (n = 3). C) Lum-
bar DRG neurons from gp120/hCD4 injured rats on POD14 
exhibited CCR2 mRNA transcripts in neurons of all sizes (n 
= 10). D) Lumbar DRG neurons from a rat subjected to 
gp120/hCD4 treatment only exhibited CCR2 immunoposi-
tive small and medium diameter sensory neurons (n = 10). E) 
In rats treated with a combination of gp120/hCD4 and ddC 
and sacrificed at POD21, many lumbar DRG neurons exhib-
ited CCR2 mRNA transcripts. F) CCR2 immunoreactivity 
was also present in numerous neurons at POD21 after com-
bined gp120/hCD4 and ddC treatment. Scale bar: 50 um.Page 7 of 18
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The CCR2 chemokine receptor colocalized with IB4 and TRPV1, markers of nociceptive neurons, after injuryFigure 3
The CCR2 chemokine receptor colocalized with IB4 and TRPV1, markers of nociceptive neurons, after injury. 
A) Many lumbar DRG neurons in vehicle-treated rat sensory neurons were positive for IB4, a neuronal phenotype that distin-
guishes some C-fiber nociceptors (red cells), however there was no expression of the CCR2 protein. B) After perineural 
gp120/hCD4 treatment, CCR2 protein expression (green cells) was upregulated, and co-localized with IB4. C) Both gp120/
hCD4 and ddC treatment resulted in an upregulation of CCR2 expression (green cells) in many small and medium diameter 
neurons. Again, CCR2 co-localized in a number of IB4 positive cells. D) The TRPV1 channel is present on many nociceptive 
neurons and is involved in the neuropathic pain mechanism. Under normal conditions, TRPV1 was expressed in neurons (red 
cells). E) After gp120/hCD4 treatment, CCR2 expression is upregulated (green cells) and colocalized with TRPV1. F) After the 
combination of gp120/hCD4 and ddC treatments, again CCR2 was upregulated to a similar degree as gp120/hCD4 treatment 
alone and exhibited some colocalizations with TRPV1. G) The percentage of CCR2-positive cells that co-localized with IB4 and 
TRPV1. CCR2 receptor expression was upregulated after gp120/hCD4 alone and the combination of gp120/hCD4 and ddC 
treatments. Most cells were of small and medium diameter. Approximately half of the CCR2-positive cells also colocalized with 
IB4 or TRPV1. Sham treatment did not result in an upregulation of CCR2 protein expression. IB4 and TRPV1 were expressed 
in all conditions, and did not differ significantly between groups. Yellow arrows: colocalizing neurons; white arrows: non-colo-































A CCR2/IB4 CCR2/IB4 CCR IB42/B C
CCR2/TRPV1 CCR2/TRPV1 CCR2/TRPV1
GP120 GP120+ddC Sham







Molecular Pain 2009, 5:48 http://www.molecularpain.com/content/5/1/48expression did not change appreciably following vehicle
treatment (Fig. 4A, B) or perineural gp120/hCD4 treat-
ment (Fig. 4C, D). In contrast, combined treatment of ani-
mals with gp120/hCD4 and ddC produced an increase in
the number of neurons expressing CXCR4 protein by
POD21 in the lumbar DRG ipsilateral to the nerve lesion.
Notably satellite cells under these conditions lacked both
CXCR4 mRNA transcripts and protein expression (Fig. 4E,
F).
To further characterize changes in CXCR4 receptor follow-
ing gp120/ddC treatment, colocalization experiments
were performed with IB4 and TRPV1. Under normal con-
ditions, there was a basal level of neuronal CXCR4 expres-
sion (10.2 ± 0.44%). Colocalization of CXCR4 and either
IB4 or TRPV1 was limited to only 3.8 ± 0.3% or 3.9 ±
0.13% of the total neurons counted respectively (Fig. 5A,
D, G). This is not surprising because the CXCR4 expres-
sion seen under these conditions is predominantly
observed in non-neuronal cells. gp120/hCD4 treatment
did not change the number of colocalized cells (Fig. 5B, E,
and 5G).
After the combination of gp120/hCD4 and ddC, there was
an increase in the number of CXCR4 immunopositive
neurons (35.1 ± 1.6%) (Fig. 5C, F, G). The percentage of
total neurons colocalized with either IB4 or TRPV1
increased to 17.1 ± 1% and 15.7 ± 8% of total neurons
counted, respectively.
Changes in chemokine expression following perineural 
gp120/hCD4 alone and in combination with ddC 
treatment
The number of cells exhibiting MCP1 (immunoreactivity)
or SDF1 (mRNA transcripts), the respective ligands for the
CCR2 and CXCR4 receptors, were also analyzed using the
both injury paradigms. Under sham conditions, there
were virtually no MCP1 immunopositive neurons in the
lumbar DRG (Fig. 6A). In sharp contrast, numerous
MCP1 immunopositive neurons were present in lumbar
ganglia of the gp120/hCD4 treated rats by POD 14 (Fig.
6B). There was also a complete lack of MCP1 immunopo-
sitive non-neuronal cells in injured DRG at any time
point.
MCP1 immunopositive neurons were also present in the
DRG of animals treated with both gp120/hCD4 and ddC
combined (Fig. 6C) as previously observed [15]. The
number of MCP1 immunopositive neurons present in the
lumbar DRG following the combined injury was similar
to numbers present in gp120/hCD4 treatment condition
(data not shown).
Previous studies of neuropathic injury in rodents have
demonstrated ddC treatment induced changes in SDF1/
CXCR4 signaling by neurons [22]. Lumbar DRG in the
naïve (data not shown), vehicle treated and gp120/hCD4
only treated rats were largely devoid of the SDF1 mRNA
transcripts with the exception of the occasional neuron
(Fig. 6D, E). In sharp contrast, following the combination
of gp120/hCD4 and ddC injury paradigm, mRNA tran-
Expression of CXCR4 in rat lumbar DRG ipsilateral to gp120/hCD4 nerve treatment and following the combination of gp120/hCD4 and ddC treat entsFigure 4
Expression of CXCR4 in rat lumbar DRG ipsilateral 
to gp120/hCD4 nerve treatment and following the 
combination of gp120/hCD4 and ddC treatments. A) 
CXCR4 mRNA transcripts present in lumbar DRG removed 
from vehicle-treated rodents at post-operative day (POD)14. 
Many non-neuronal cells strongly expressed CXCR4 mRNA. 
This data is not unlike previous observations [22]. B) 
CXCR4 protein levels after sham treatment were mainly 
expressed in non-neuronal cells and only occasional neurons. 
After gp120/hCD4 treatment, the mRNA and protein pat-
terns of expression for the CXCR4 receptor did not change 
by POD14, when compared to sham treated animals (C,D). 
E) gp120/hCD4 treatment, in combination with ddC treat-
ment produced upregulation of CXCR4 mRNA expression in 
neurons of all sizes by POD21. F) Protein expression for the 
CXCR4 receptor was also upregulated in neurons of mostly 
small and medium diameters after the combination of gp120/
hCD4 and ddC treatments at POD21. Arrows: positive cells; 
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The CXCR4 chemokine receptor colocalizes with IB4-binding and TRPV1-immunopositive neurons following injuryFigure 5
The CXCR4 chemokine receptor colocalizes with IB4-binding and TRPV1-immunopositive neurons following 
injury. A) Under sham conditions, CXCR4 was expressed in mainly non-neuronal cells, along with occasional neurons. Many 
lumbar DRG neurons in vehicle-treated rat sensory neurons were positive for IB4, a neuronal phenotype that distinguishes 
some C-fiber nociceptors (green cells), however there was little colocalization of CXCR4 with IB4-binding cells. B) Fourteen 
days after gp120/hCD4 treatment, CXCR4 and IB4 protein expression (red cells) patterns did not change, when compared to 
sham treated animals C) Both gp120/hCD4 and ddC treatment resulted in an upregulation of CXCR4 expression in many 
small and medium diameter neurons by POD21. CXCR4 co-localized in a number of IB4-positive cells. D) Under normal con-
ditions, TRPV1 was expressed in neurons (green cells). CXCR4 was expressed in non-neuronal cells, and there was little co-
localization with TRPV1. E) gp120/hCD4 treatment did not produce changes in the distribution or colocalization of CXCR4 
and TRPV1. F) Numerous neurons exposed to the combination of gp120/hCD4 and ddC treatment exhibited both CXCR4 
upregulation and colocalization with TRPV1 by POD21. G) The percentage of CXCR4-positive cells that co-localized with IB4 
and TRPV1. CXCR4 receptor expression was present under sham conditions and did not change following gp120 treatment. 
Following the combination of gp120/hCD4 and ddC treatment, CXCR4 immunoreactivity was observed approximately half of 
the IB4-binding and TRPV1-immunopositive cells of small and medium diameter. Data represents mean ± SE; p < 0.01, n = 10. 
Yellow arrows: neuronal colocalization; white arrows: single-labeled neurons. Scale Bar: 50 um.
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to injury in virtually all neurons (Fig. 6E).
Chemokines increase [Ca2+]i in DRG cells subjected to 
gp120/hCD4 treatment alone and in combination with 
ddC
Activation of chemokine receptors expressed by primary
sensory neurons results in excitation and in the increase in
the intracellular Ca2+concentration [5]. Fura-2 based Ca
imaging of chemokine induced increases in [Ca2+]i in
acutely isolated rat DRG neurons was used as a measure of
functional chemokine receptor expression. DRG cells
were acutely isolated from the ipsilateral side of nerve
injured animals and sham controls. For all experiments,
the chemokines MCP1, SDF1 and IP-10 were added in
random order to the cells, after which capsaicin, high
K+(50 mM) and ATP were added to assess the cells' iden-
tity and viability, respectively. A response to high K+ stim-
ulation indicates the presence of voltage dependent Ca2+
channels, which is indicative of neurons. Additionally, a
positive response to capsaicin as well as high K+ indicates
the cell is a nociceptor expressing the TRPV1 channel. If
the cell did not respond to either capsaicin or K+, ATP was
added to the bathing solution. A response to ATP, which
activates purinergic receptors, without one to High K+
and/or capsaicin, indicates a non-neuronal cell, such as a
glial cell. The concentrations of chemokines used in these
experiments were all supramaximal to ensure activation of
any expressed receptors.
It was evident that a greater number of cells responded to
MCP1 application at POD 21 in the DRG ipsilateral to the
perineural gp120/hCD4 injury when compared to vehicle
treated control DRG (18.7% versus 3.2%, respectively; Fig
7A, B, and Table 1). The majority of these cells were char-
acterized as neurons based on their positive responses to
capsaicin and/or high K+ (Table 2). The number of cells
responding to SDF1 application was 4.3%, and was not
significantly different from sham animals. The number of
cells responding to either SDF1 or IP-10 application did
not change. IP-10, the ligand for the CXCR3 chemokine
receptor, was not upregulated in this animal model (data
Chemokine expression after gp120/hCD4 alone and following the combination of gp120/hCD4 and ddC treatmentFigure 6
Chemokine expression after gp120/hCD4 alone and following the combination of gp120/hCD4 and ddC treat-
ment. A) MCP1 expression, the ligand for the CCR2 receptor was absent from sham treated animals. B) After gp120/hCD4 
treatment, MCP1 expression was upregulated in mostly neurons of the DRG. C) After the combined treatments of gp120/
hCD4 and ddC, MCP1 expression was upregulated in a similar manner to that seen in the gp120/hCD4 only treatment. D) 
SDF1, the ligand for CXCR4, had a basal level of mRNA expression, with the occasional neuron staining positive for the chem-
okine E) After gp120/hCD4 treatment, the level of SDF1 mRNA expression did not change appreciably, when compared to 
sham treated animals. F) Following gp120/hCD4 and ddC treatments, SDF1 mRNA expression was upregulated in neurons of 
all sizes. Arrows: positive cells; arrowheads: negative cells. Scale bar: 100 um.
A B C 
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the observed upregulated CCR2 expression in sensory
neurons following perineural gp120/hCD4 treatment.
The chemokine sensitivity profile also changed after the
rats were treated with the combination of gp120/hCD4
and ddC as the number of cells responding to SDF1 appli-
cation at POD 21 increased from 4.8% in vehicle treated
animals to 40% in cells derived from injured animals (Fig
7C, Table 1). The number of cells that responded to MCP1
in tissue derived from gp120/hCD4 and ddC treated ani-
mals did not differ from gp120/hCD4 treatment condi-
tion (17.5% and18.7%, respectively). Furthermore, most
of the cells responding to MCP1 and SDF1 application
were neurons, based on their response profile to capsai-
cin, high K+ and ATP (Table 3). Hence, the observed
upregulation of responses to SDF1 and MCP1 application
agreed with the anatomical observations on receptor
expression described above.
Chemokine receptor antagonists transiently reverse 
mechanical hypernociceptive behavior after injury
The CCR2 receptor antagonist (CCR2 RA-[R]) and the
CXCR4 receptor antagonist, AMD3100, have previously
been shown to reverse mechanical hypernociception in
Chemokines increased [Ca2+]i levels in acutely isolated rat DRG cells following the injury schemesFigure 7
Chemokines increased [Ca2+]i levels in acutely iso-
lated rat DRG cells following the injury schemes. The 
figure shows examples of responses of cells acutely isolated 
from rat DRGs ipsilateral to the gp120/hCD4 and following 
gp120/hCD4 and ddC nerve injury at POD 21. Under normal 
conditions, cells rarely responded to any chemokine, but did 
respond to other stimuli such as high K or capsaicin (A). 
However, there was an increased responsiveness of the cells, 
the majority of which could be characterized as neurons, by 
POD21 in both the gp120/hCD4 only (B) and the combina-
tion of gp120/hCD4 with ddC injuries (C). For all experi-
ments, MCP1 (M), IP-10 (I) and SDF1 (S) were applied at a 
concentration of 100 nM. Capsaicin (C) and high K (K) were 
applied at concentrations of 100 nM, 50 mM, respectively.
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Table 1: Percentage of cells responding to chemokine 
application in dissociated DRG ipsilateral to nerve injury at POD 
21
Chemokine Sham gp120/hCD4 gp120/hCD4 +ddC
MCP1 3.2% 18.7%* 17.5% *
SDF1 4.8% 4.3% 40%**
IP10 6.5% 5.9% 7.5%
*p < 0.05 and ** p < 0.01 when compared to sham
Minimum of 50 cells/treatment group
Calcium imaging was used to monitor the change in [Ca2+]i after 
chemokines were applied to acutely dissociated DRG from sham or 
injured rats. The number of cells responding to MCP1 application 
increased significantly by 21 days after gp120/hCD4 and following the 
combination of gp120/hCD4 and ddC treatment. The number of cells 
responding to SDF1 application increased only after the combination 
of gp120/hCD4 and ddC treatments.
Table 2: Identity of cells responding to chemokine application at 
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lesion (CCR2 RA-[R]) and, ddC treatment (AMD3100)
[22,24]. To assess the ability of these receptor antagonists
to reverse injury induced changes in behavioral responses
we administered a single injection of CCR2 RA-[R] (i.p.,
10 mg/kg) 14 days afterperineural gp120/hCD4 treat-
ment. Treatment with CCR2 RA-[R] transiently reversed
mechanical hypernociception (Fig. 8A). In the same
group of animals, administration of the CXCR4 antago-
nist, AMD3100 (i.p., 5 mg/kg) at 17 days after perineural
gp120/hCD4 treatment did not alter the presence of
mechanical hypernociceptive behavior (Fig. 8A). In con-
trast, when administered to gp120/hCD4 and ddC treated
animals at POD 21, AMD3100 (i.p., 5 mg/kg) transiently
reversed mechanical hypernociceptive behavior, while
administration of CCR2-RA-[R] (i.p., 10 mg/kg) pro-
duced no change in mechanical hypernociceptive behav-
ior (Fig. 8B). The effect of the AMD3100 in gp120/hCD4
and ddC treated animals was similar to effect on animals
treated only with ddC [22].
Discussion
Previous studies have demonstrated the important role of
chemokine signaling in neuropathic pain models
[7,22,24,34]. It was previously shown that NRTI treat-
ment alone resulted in both increased mechanical hyper-
sensitivity and upregulation of CXCR4/SDF1 signaling in
the DRG [22]. While this previous study was informative
in beginning to understand the mechanisms underlying
this type of neuropathic pain, we wished to observe the
degree to which the HIV1 viral coat protein, gp120 inter-
acts with ddC and if this changes the drug associated pat-
tern of chemokine signaling and chronic nociceptive
behavior. To accomplish this, NRTI treatment was com-
bined with perineural exposure to gp120/hCD4. Impor-
tantly, the T-tropic HIV1 viral coat protein, gp120 IIIB,
was primed with hCD4, which facilitates high affinity
binding to CXCR4 chemokine receptors [17]. T-tropic ver-
sions of HIV1 generally emerge later in the course of the
disease and it is possible that M-tropic versions would
produce a different set of phenomena. However, there is
no consensus at this point in time as to the correlation
between viral tropism and the appearance of clinical neu-
ropathic pain. Indeed, it is quite possible that both types
of virus contribute to this phenomenon [35]. The model
we have used was previously shown to result in mechani-
cal hypernociception and reduced intraepidermal nerve
fiber density, which is similar to what is seen in the clini-
cal setting [10].
It was hypothesized that while administration of either an
NRTI or gp120/hCD4 might result in upregulation of
chemokine signaling, the combination of gp120/hCD4
and an NRTI might result in a synergistic effect. In rats fol-
lowing gp120/hCD4 treatment alone, mechanical hyper-
nociception developed as early as POD 3 and lasted until
at least POD 28. Together with behavioral changes, pro-
nounced increases in MCP1/CCR2, but not SDF1/CXCR4
chemokine signaling events were observed. The role of
enhanced MCP1/CCR2 signaling in gp120/hCD4 injury
induced mechanical hypernociception was confirmed by
the reversal of nociceptive behavior on treatment with a
CCR2 RA. The combination of gp120/hCD4 and ddC pro-
duced mechanical hypernociception similar to gp120/
hCD4 alone, along with enhanced MCP1/CCR2 and
SDF1/CXCR4 signaling. However, following this treat-
ment combination only AMD3100 a CXCR4 antagonist
was effective in reversing mechanical hypernociception.
Taken together, these results suggest a role for both SDF1/
CXCR4 and MCP1/CCR2 signaling in HIV1/ddC associ-
ated mechanical hypernociceptive behavior (Table 4).
Several studies on the mechanisms underlying chronic
pain have focused on the CCR2 and CXCR4 receptors, and
their respective ligands, MCP1 and SDF1. This is because
along with a previous study, where the importance of
CXCR4/SDF1 signaling in a NRTI-associated neuropathic
pain model was demonstrated, other studies had shown
that peripheral nerve injury resulted in the upregulation
of CCR2 and its ligand MCP1 in DRG neurons
[7,22,24,36-38]. Indeed, administration of a CCR2 RA
blocked mechanical hypernociception in a focal demyeli-
nation model in which both MCP1 and CCR2 expression
were upregulated [24,38]. Furthermore, a study by
Abbadie and colleagues [34] demonstrated that mice lack-
ing the CCR2 receptor lack neuropathic pain impairment
after injury.
We observed that after gp120/hCD4 treatment, MCP1/
CCR2 signaling events were upregulated in neurons of the
affected DRG. It has been shown that MCP1 has an excita-
tory effect on DRG sensory neurons after injury [7]. Work
from our laboratory has also shown MCP1 can be pack-
aged into secretory vesicles and released upon depolariza-
tion [39]. Thus, MCP1 could be released by DRG sensory
neurons and affect neighboring, uninjured CCR2 express-
ing neurons increasing their excitability [7]. It is believed
that chemokines can produce their excitatory effect by
activating the phospholipase C-induced degradation of
Table 3: Identity of cells responding to chemokine application at 
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Effect of CCR2 receptor antagonist (RA) and CXCR4 RA on gp120/hCD4 alone and following gp120/hCD4 and ddC-induced decrease in paw withdrawal thresholds (PWT) in the ratFigure 8
Effect of CCR2 receptor antagonist (RA) and CXCR4 RA on gp120/hCD4 alone and following gp120/hCD4 and 
ddC-induced decrease in paw withdrawal thresholds (PWT) in the rat. Mechanical hypernociception for the two 
models was attenuated with antagonists to chemokine receptors. A) CCR2 receptor antagonist administration attenuated 
existing nociceptive behavior due to gp120/hCD4 administration. In the same animals, intraperitoneal administration of the 
CXCR4 receptor antagonist, AMD3100, did not affect gp120/hCD4 induced mechanical hypernociception. B) Animals sub-
jected to a combination of gp120/hCD4 and ddC exhibited significant increases in PWT following the administration of 
AMD3100. Data represent means ± SE; *p < 0.01, n = 10 per treatment condition. POD: post-operative day after gp120/hCD4 
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TRPV1 channels [39,40]. In addition, activation of chem-
okine receptors clearly has excitatory actions mediated
through effects on Na and K currents [6]. Thus, MCP1 may
potentially excite TRPV1 expressing as well as other noci-
ceptive neurons. Alternatively, MCP1 immunopositive
fibers in the spinal cord dorsal horn may release the chem-
okine and activate neurons and/or non-neuronal cells
[37,41,42].
The increased mechanical hypersensitivity seen here
agrees with previous studies, where it was shown that
peripheral nerve exposure to gp120 (albeit without
hCD4) resulted in mechanical hypersensitivity for up to
50 postoperative days, with a lack of thermal or cold
hyperalgesia [9,15]. While the lack of thermal behavior is
unusual for a rodent neuropathic pain models, several
models do indeed lack thermal hyperalgesia, including a
fibromyalgia model [43,44] and focal demyelination of
the sciatic nerve [24]. Perhaps more importantly, there are
a large percentage of patients with HIV-1 associated neu-
ropathic pain who do not report thermal hyperalgesia
[45].
There have been several mechanisms suggested for
explaining the deleterious effects of HIV-1 on sensory
neuron function. gp120, independent of the conforma-
tional change by hCD4, produces neuritic and axonal
degeneration of DRG neurons in culture via a chemokine
receptor dependent mechanism [10,46]. It was also
observed that the use of gp120 (without the addition of
hCD4) produced the release of proinflammatory
cytokines such as TNFα, IL-6 and IL1-β [14,15]. Whether
the addition of hCD4 induced conformational changes to
gp120 augments these inflammatory responses in the
rodent is unknown. However, the combination of the
gp120 induced cascades of pro-inflammatory cytokine
production and release likely lead to both the develop-
ment of neuropathic hypernociceptive behavior in the
rodent and chronic expression of nociceptive chemokines
[47].
The combination of a T-tropic form of gp120 with hCD4
did not alter the expression or functional signaling of
SDF1/CXCR4 in the DRG, however, increased expression
of both MCP1 and CCR2 was observed, in addition to
increased functional signaling via CCR2. The changes in
MCP1 resemble those observed by Wallace and colleagues
(2007) using gp120 alone as well as those observed in
other injury models [7,24]. The increased functional sign-
aling of MCP1/CCR2 may be due to an indirect mecha-
nism by which CXCR4 receptors located on Schwann cells
in the peripheral nerve are activated by the gp120/hCD4.
These cells may release RANTES within the perineural
environment and release of TNFα in the DRG [10]. As
mentioned previously, TNFα could then initiate an
"inflammatory" cascade and increased neuronal expres-
sion of MCP1 and CCR2. Hence, the importance of
MCP1/CCR2 signaling following administration of a T-
tropic gp120/hCD4 may involve a hierarchy of effects
wherein initial interactions with CXCR4 lead to down-
stream changes in MCP1/CCR2 functional signaling. It
should be noted that direct gp120/hCD4 signaling via
CXCR4 was not the causative effect, as AMD3100 did not
alter hypernociceptive behavior in this model.
Also, consistent with this model, administration of a
CCR2 RA was effective in transiently eliminating the
mechanical hypernociceptive behavior observed after
gp120/hCD4 treatment. This could be due to the fact that
upregulation of chemokine receptors can be expressed in
different populations of sensory neurons following nerve
injury [48,49]. In our experiments up to 57% of the cells
that upregulated CCR2 were positive for IB4, a marker of
non-peptidergic C-fiber nociceptors. Nearly the same
numbers of CCR2 immunopositive neurons were colocal-
ized with a nonoverlapping peptidergic population of
nociceptors that exhibited the cation channel, TRPV1.
This is an important observation as many groups believed
that the reversal of injury induced mechanical hypernoci-
ceptive behavior observed with either the use of mice lack-
ing CCR2 or CCR2 RA was mechanistically due to CCR2
bearing non-neuronal cells in the CNS as microglial cells
[34,42,50,51]. A more recent publication provides direct
evidence that CCR2 expression is limited to the DRG fol-
lowing peripheral nerve injury [38].
An important goal of this series of experiments was to
model the neuropathic pain syndromes reported by HIV-
1 positive individuals being treated with NRTIs. To do
this, the perineural gp120/hCD4 injury was combined
with a known neurotoxic NRTI, ddC. We have previously
shown that ddC treatment alone resulted in the upregula-
tion of CXCR4 and SDF1 mostly in glia, but also in some
neurons of the DRG. Despite a report to the contrary [15],
we did not observe increased expression of either MCP1
or the CCR2 following ddC treatment. This discrepancy
Table 4: Summary figure of gp120/hCD4 and NRTI treatments
gp120/hCD4 ddC gp120/hCD4+ddC
CXCR4 No change ↑
SDF1 No change ↑ ↑
CCR2 ↑ No change ↑
MCP1 ↑ No change ↑
Behavior Mechanical Mechanical, thermal Mechanical, thermalPage 15 of 18
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dentified factors. However, when both treatments were
combined, rather than observing the increased expression
of either MCP1/CCR2 or SDF1/CXCR4, both chemokine
signaling systems were upregulated and this was observed
to occur mostly in neurons. Moreover, the degree to which
CXCR4 upregulated was much greater than that observed
following ddC treatment alone. This synergistic effect of
the two independent treatments is interesting, and may
mechanistically facilitate chronic maintenance of
mechanical hypernociception in the rodent and clinical
neuropathic pain reported in HIV-1 associated peripheral
neuropathy.
The combination of perineural gp120/hCD4 treatment
with ddC produced increased neuronal expression of both
CXCR4 and CCR2 receptors together with their respective
ligands, SDF1 and MCP1 in rather distinct subpopula-
tions of sensory neurons. Almost equal numbers of chem-
okine receptor immunopositive neurons colocalized with
either IB4 or TRPV1; both of which are mutually exclusive
markers of nociceptors [48,49]. As such, it is quite possi-
ble that the population of CCR2 or CXCR4 positive neu-
rons is directly linked to the production of chronic
neuronal hyperexcitability.
Perhaps a more important observation is that following
the combination of the perineural gp120/hCD4 treatment
with the NRTI treatment, mechanical hypernociceptive
behavior in the rodent became a CXCR4 receptor depend-
ent phenomenon. In the combined treatment model, the
level of SDF1/CXCR4 signaling increased from 4% (under
sham or gp120/hCD4 treatment condition) to 40%. Con-
current with the change in SDF1/CXCR4 functional sign-
aling was the ability of the CXCR4 antagonist AMD3100
to effectively produce a transient reversal of mechanical
hypernociceptive behavior. This CXCR4 dependent effect
occurred despite the presence of ongoing injury induced
MCP1/CCR2 signaling.
The behavioral effect of AMD3100 under the conditions
of both injury induced CCR2 and CXCR4 functional sign-
aling may be due to the possibility that chemokine recep-
tors under these conditions may form homo- and
heterodimers, which may ultimately alter their signaling
properties. For example, it was recently demonstrated that
CCR2 and CXCR4 could form heterodimers resulting in
receptors with distinct properties [52]. Furthermore, a
specific antagonist to one of the receptors was observed to
inhibit binding of a chemokine ligand to the partner
receptor in vitro and in vivo [53]. These results have impor-
tant implications in the present pain model, where an
antagonist to the CXCR4 receptor was effective in com-
pletely attenuating the pain behavior despite the fact that
functional CCR2 receptors were simultaneously upregu-
lated.
Another difference between gp120/hCD4 alone or in
combination with the ddC was the observed thermal
hypernociceptive behavior in the combination injury. It
was previously shown that administration of ddC alone
resulted in an increased hypersensitivity to a thermal stim-
ulus [54], yet gp120 (without the addition of hCD4) treat-
ment alone did not result in thermal hyperalgesic
behavior [15]. Therefore, our results are consistent with
these previous studies. One possible mechanism that has
been suggested for the additive effect of the ddC is that
this compound quite often results in mitochondrial dys-
function. Studies have also shown that a number of mito-
chondrial abnormalities have been linked to neuropathic
pain symptoms [54,55].
In summary, using a combined model of NRTI and HIV-1
associated peripheral neuropathy, we have demonstrated
that two different chemokine signaling systems may inter-
act and result in the maintenance of this neuropathic pain
syndrome. These results, taken with previous studies, sug-
gest an important role for the SDF1/CXCR4 and MCP1/
CCR2 chemokine signaling systems in HIV-1 associated
painful neuropathies and are perhaps potential therapeu-
tic targets.
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